Table 2.
Baseline clinical predictors of ixekizumab discontinuation through multivariate analysis.
| Clinical Variables | OR | 95%CI | p Value |
|---|---|---|---|
| Discontinuation of Ixekizumab | |||
| Multivariate analysis | |||
| Age | 0.99 | 0.97–1.03 | 0.980 |
| Male Sex | 1.21 | 0.60–2.27 | 0.591 |
| Disease duration ≤ 2 years | 1.51 | 0.76–2.99 | 0.235 |
| HLA-B27 | 2.72 | 0.90–8.23 | 0.076 |
| Multivariate analysis | |||
| Age | 0.99 | 0.96–1.02 | 0.991 |
| Male Sex | 1.42 | 0.64–3.16 | 0.386 |
| Comorbidity | 1.10 | 0.47–2.57 | 0.825 |
| Obesity | 0.78 | 0.37–1.64 | 0.511 |
| Multivariate analysis | |||
| Age | 1.01 | 0.98–1.03 | 0.922 |
| Male Sex | 1.09 | 0.53–2.25 | 0.811 |
| Axial Disease | 1.67 | 0.86–3.25 | 0.133 |
| Skin involvement | 0.89 | 0.38–2.07 | 0.791 |
| Multivariate analysis | |||
| Age | 0.99 | 0.97–1.03 | 0.989 |
| Male Sex | 1.17 | 0.57–2.43 | 0.664 |
| Previous csDMARDs | 1.26 | 0.49–3.28 | 0.630 |
| Previous bDMARDs | 1.07 | 0.52–2.19 | 0.852 |
Footnotes: OR, odds ratio; CI, confidence interval; HLA, Human Leukocyte antigen; csDMARDs, conventional synthetic Disease Modifying Antirheumatic Drugs; bDMARDs, biologic Disease Modifying Antirheumatic Drugs.